Annals of Surgical Oncology

, Volume 18, Issue 2, pp 431–438 | Cite as

Precision Hepatic Arterial Irinotecan Therapy in the Treatment of Unresectable Intrahepatic Cholangiocellular Carcinoma: Optimal Tolerance and Prolonged Overall Survival

  • Suzanne C. Schiffman
  • Tiffany Metzger
  • Gregory Dubel
  • Tomas Andrasina
  • Ivan Kralj
  • Cliff Tatum
  • Kelly M. McMasters
  • Charles R. Scoggins
  • Robert C. G. Martin
Hepatobiliary Tumors

Abstract

Background

Unresectable intrahepatic cholangiocellular carcinoma (ICC) carries a poor prognosis, and there are few chemotherapeutic treatments to prolong survival. The purpose of this study was to assess the efficacy of drug-eluting bead (DEB) therapy by transarterial infusion for unresectable ICC.

Methods

A prospective multicenter study of ICC patients who received hepatic arterial DEB therapy.

Results

Twenty-four patients with unresectable ICC were treated with DEB. Ten patients (41.6%) had recurrent ICC after prior radiofrequency ablation (n = 3) or hepatectomy (n = 7). Twenty patients (80%) had received prior chemotherapy, mostly of gemcitabine (n = 8) or Eloxatin (n = 6). The percent of overall liver involvement was < 25% (n = 8), 26% to 50% (n = 11), and > 50% (n = 4). Ten patients (40%) had sites of extrahepatic disease located at lymph nodes (n = 5), bone (n = 2), peritoneum (n = 1), lung (n = 1), and mouth (n = 1). A total of 42 DEB treatments were administered. Eight were administered in combination with systemic chemotherapy of FOLFOX (n = 4) or Gemzar (n = 4). Twelve patients (48%) received a second treatment, and 4 patients (16%) received a third treatment. The median length of stay was 23 h (23–72 h). Eleven adverse reactions (26.2%) were reported. Of these, 7 (63.6%) were minor (less than grade 3). One patient died from hepatorenal syndrome. The disease of one patient was downstaged to resection. After a median follow-up of 13.6 months, the median overall survival of a multitherapeutic regimen with DEB therapy was significantly greater than chemotherapy alone (17.5 vs. 7.4 months; P = 0.02).

Conclusions

Bead therapy is safe and effective in patients with unresectable ICC. There is a marked survival benefit when DEB therapy is used as adjunctive therapy.

References

  1. 1.
    Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005;128:620–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Choi SB, Kim KS, Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol. 2009;16:3048–56.CrossRefPubMedGoogle Scholar
  3. 3.
    Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J Gastroenterol. 2009;15:4240–62.CrossRefPubMedGoogle Scholar
  4. 4.
    Shaib YH, El-Serag HB, Nooka AK, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol. 2007;102:1016–21.CrossRefPubMedGoogle Scholar
  5. 5.
    Lim JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR Am J Roentgenol. 2003;181:819–27.PubMedGoogle Scholar
  6. 6.
    Jan YY, Yeh CN, Yeh TS, Hwang TL, Chen MF. Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma. World J Surg. 2005;29:894–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Choi CW, Choi IK, Seo JH, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol. 2000;23:425–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Rocha FG, Matsuo K, Blumgart LH, Jarnagin WR. Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience. J Hepatobiliary Pancreat Surg. (in press).Google Scholar
  9. 9.
    Tan JC, Coburn NG, Baxter NN, Kiss A, Law CH. Surgical management of intrahepatic cholangiocarcinoma: a population-based study. Ann Surg Oncol. 2008;15:600–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Jarnagin WR, Fong Y, Dematteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507–17.CrossRefPubMedGoogle Scholar
  11. 11.
    Yang J, Yan LN. Current status of intrahepatic cholangiocarcinoma. World J Gastroenterol. 2008;14:6289–97.CrossRefPubMedGoogle Scholar
  12. 12.
    Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224:463–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248:84–96.CrossRefPubMedGoogle Scholar
  14. 14.
    Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51(Suppl 6):VI1–VI9.CrossRefPubMedGoogle Scholar
  15. 15.
    Yamamoto M, Takasaki K, Otsubo T, Katsuragawa H, Katagiri S. Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2001;8:154–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Weber SM, Jarnagin WR, Klimstra D, et al. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 2001;193:384–91.CrossRefPubMedGoogle Scholar
  17. 17.
    Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007;96:896–902.CrossRefPubMedGoogle Scholar
  18. 18.
    Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol. 2005;16(2):93–96.CrossRefPubMedGoogle Scholar
  19. 19.
    Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology. 2000;47:644–9.PubMedGoogle Scholar
  20. 20.
    Gerhards MF, Van Gulik TM, Gonzalez GD, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg. 2003;27:173–9.PubMedGoogle Scholar
  21. 21.
    Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. (in press).Google Scholar
  22. 22.
    Fiorentini G, Aliberti C, Benea G, et al. TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. Hepatogastroenterology. 2008;55:2077–82.PubMedGoogle Scholar
  23. 23.
    Fiorentini G, Aliberti C, Del CA, et al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo 2009;23:131–7.PubMedGoogle Scholar
  24. 24.
    Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. (in press).Google Scholar
  25. 25.
    Malagari K. Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead. Expert Rev Anticancer Ther. 2008;8:1643–50.CrossRefPubMedGoogle Scholar
  26. 26.
    Martin RC, Robbins K, Tomalty D, et al. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol. 2009;7:80.CrossRefPubMedGoogle Scholar
  27. 27.
    Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res. 2006;26:3793–5.PubMedGoogle Scholar
  28. 28.
    Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474–81.CrossRefPubMedGoogle Scholar
  29. 29.
    Levine MN, Julian JA. Registries that show efficacy: good, but not good enough. J Clin Oncol. 2008;26:5316–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Martin RC, Joshi J, Robbins K, Tomalty D, O’Hara R, Tatum C. Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol. (in press).Google Scholar
  31. 31.
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.CrossRefPubMedGoogle Scholar
  32. 32.
    Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006;42:1031–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.CrossRefPubMedGoogle Scholar
  34. 34.
    Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115:616–23.CrossRefPubMedGoogle Scholar
  35. 35.
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMedGoogle Scholar
  36. 36.
    Sanz-Altamira PM, O’Reilly E, Stuart KE, et al. A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol. 2001;12:501–4.CrossRefPubMedGoogle Scholar
  37. 37.
    Ducreux M, Van CE, Van Laethem JL, et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer. 2005;41:398–403.CrossRefPubMedGoogle Scholar
  38. 38.
    Kim MJ, Oh DY, Lee SH, et al. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. BMC Cancer. 2008;8:374.CrossRefPubMedGoogle Scholar
  39. 39.
    Rao S, Cunningham D, Hawkins RE, et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer. 2005;92:1650–4.CrossRefPubMedGoogle Scholar
  40. 40.
    Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005;23:2332–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Knox JJ, Hedley D, Oza A, et al. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol. 2004;15:770–4.CrossRefPubMedGoogle Scholar
  42. 42.
    Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.CrossRefPubMedGoogle Scholar
  43. 43.
    Lee GW, Kang JH, Kim HG, et al. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol. 2006;29:127–31.CrossRefPubMedGoogle Scholar
  44. 44.
    Kim ST, Park JO, Lee J, et al. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer. 2006;106:1339–46.CrossRefPubMedGoogle Scholar
  45. 45.
    Zeng ZC, Tang ZY, Fan J, et al. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients. Cancer J. 2006;12:113–22.PubMedGoogle Scholar
  46. 46.
    Fiorentini G, Aliberti C, Turrisi G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 2007;21:1085–91.PubMedGoogle Scholar
  47. 47.
    Aliberti C, Benea G, Tilli M, Fiorentini G. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol. 2008;31:883–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Fiorentini G, Rossi S, Bonechi F, et al. Intra-arterial hepatic chemoembolization in liver metastases from neuroendocrine tumors: a phase II study. J Chemother. 2004;16:293–7.PubMedGoogle Scholar
  49. 49.
    Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33(3):541–51.CrossRefPubMedGoogle Scholar
  50. 50.
    Cantore M, Mambrini A, Fiorentini G, et al. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer. 2005;103:1402–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Mambrini A, Del FA, Pacetti P, et al. Intra-arterial and systemic chemotherapy plus external hyperthermia in unresectable biliary cancer. Clin Oncol (R Coll Radiol). 2007;19:805–6.Google Scholar
  52. 52.
    Melichar B, Cerman J Jr, Dvorak J, et al. Regional chemotherapy in biliary tract cancers—a single institution experience. Hepatogastroenterology. 2002;49:900–6.PubMedGoogle Scholar
  53. 53.
    Mambrini A, Guglielmi A, Pacetti P, et al. Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study. Anticancer Res. 2007;27:3009–13.PubMedGoogle Scholar
  54. 54.
    Feisthammel J, Schoppmeyer K, Mossner J, et al. Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial. Am J Clin Oncol. 2007;30:319–24.CrossRefPubMedGoogle Scholar
  55. 55.
    Lee MA, Woo IS, Kang JH, Hong YS, Lee KS. Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol. 2004;130:346–50.CrossRefPubMedGoogle Scholar
  56. 56.
    Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer. 2008;98:309–15.CrossRefPubMedGoogle Scholar
  57. 57.
    Sasaki T, Isayama H, Nakai Y, et al. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2010;65(6):1101–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Takezako Y, Okusaka T, Ueno H, et al. Phase II study of cisplatin, epirubicin and continuous infusion of 5-fluorouracil in patients with advanced intrahepatic cholangiocellular carcinoma (ICC). Hepatogastroenterology. 2008;55:1380–4.PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2010

Authors and Affiliations

  • Suzanne C. Schiffman
    • 1
  • Tiffany Metzger
    • 1
  • Gregory Dubel
    • 2
  • Tomas Andrasina
    • 3
  • Ivan Kralj
    • 4
  • Cliff Tatum
    • 5
  • Kelly M. McMasters
    • 1
  • Charles R. Scoggins
    • 1
  • Robert C. G. Martin
    • 1
  1. 1.Division of Surgical Oncology, Department of Surgery, James Graham Brown Cancer CenterUniversity of LouisvilleLouisvilleUSA
  2. 2.Division of Interventional Radiology, Department of Diagnostic ImagingWarren Alpert Medical School of Brown University and Rhode Island HospitalProvidenceUSA
  3. 3.Department of RadiologyFN Brno a LF MUBrnoCzech Republic
  4. 4.DiakonissenkrankenhausKlinik für Radiologie, Interventionsradiologie und NuklearmedizinKarlsruheGermany
  5. 5.Norton RadiologyNorton HealthcareLouisvilleUSA

Personalised recommendations